Cargando…

Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing

OBJECTIVES: To describe the therapeutic drug monitoring (TDM) of cefepime in non-critically ill adults and compare four different ways of dosing: conventional table-based; empirically adjusted following TDM; individualized based on a population pharmacokinetic (PopPK) model without TDM; and TDM-adju...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suttels, Véronique, André, Pascal, Thoma, Yann, Veuve, François, Decosterd, Laurent, Guery, Benoît, Buclin, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021014/ https://www.ncbi.nlm.nih.gov/pubmed/35465238 http://dx.doi.org/10.1093/jacamr/dlac043

Ejemplares similares

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
por: Buclin, Thierry, et al.
Publicado: (2020)

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective
por: Briki, Myriam, et al.
Publicado: (2023)

Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response
por: Vijiala, Sergiu, et al.
Publicado: (2022)

Prospective monitoring of cefepime in intensive care unit adult patients
por: Chapuis, Thomas M, et al.
Publicado: (2010)

Cefepime in critically ill patients: continuous infusion versus intermittent regimen
por: Georges, B, et al.
Publicado: (2001)

Cefepime-induced neurotoxicity in critically ill patients undergoing continuous renal replacement therapy: beware of dose reduction!
por: Honore, Patrick M., et al.
Publicado: (2015)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
por: Thoueille, Paul, et al.
Publicado: (2021)

Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients
por: Smith, Susan E., et al.
Publicado: (2023)

Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study
por: Chaijamorn, Weerachai, et al.
Publicado: (2018)

Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study
por: Thoueille, Paul, et al.
Publicado: (2023)

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Cefepime is Associated with Acute Encephalopathy in Critically Ill Patients: A Retrospective Case–Control Study
por: Singh, Tarun D., et al.
Publicado: (2020)

1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
por: Kois, Abigail K, et al.
Publicado: (2021)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study
por: Su, Ting-Yi, et al.
Publicado: (2017)

Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers
por: Dao, Kim, et al.
Publicado: (2020)

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration
por: Thoueille, Paul, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
por: Choong, Eva, et al.
Publicado: (2022)

Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!
por: André, Pascal, et al.
Publicado: (2022)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

Population Pharmacokinetics and Monte Carlo Simulation of Cefepime in Critically Ill Patients with Hospital-Acquired/Ventilator-Associated Pneumonia
por: Seo, Hyeonji, et al.
Publicado: (2023)

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
por: Perrottet, Nancy, et al.
Publicado: (2010)

1100. A Prospective Evaluation of Neurotoxicity Among Patients Receiving Dose-Optimized Cefepime or Meropenem With Concomitant Therapeutic Drug Monitoring
por: Smith, Brandon, et al.
Publicado: (2021)

Cefepime Dosing Requirements in Elderly Patients Attended in the Emergency Rooms
por: Ruiz-Ramos, Jesus, et al.
Publicado: (2022)

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
por: Thoueille, Paul, et al.
Publicado: (2022)

628. Utilizing Cefepime Therapeutic Drug Monitoring for Patients at Risk of or Exhibiting Signs of Neurotoxicity
por: Au, Joanna, et al.
Publicado: (2022)

Cefepime-induced encephalopathy
por: Kenzaka, Tsuneaki, et al.
Publicado: (2018)

Cefepime-Induced Encephalopathy
por: Keerty, Dinesh, et al.
Publicado: (2021)

Cefepime-Induced Neurotoxicity
por: Saini, Tanjot, et al.
Publicado: (2021)

Cefepime-Induced Delirium
por: Somoza-Cano, Francisco J, et al.
Publicado: (2021)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants
por: Zhao, Yang, et al.
Publicado: (2020)

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
por: Le Terrier, Christophe, et al.
Publicado: (2023)

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
por: Crandon, Jared L., et al.
Publicado: (2015)

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

Cefepime-Resistant Pseudomonas aeruginosa
por: Akhabue, Ehimare, et al.
Publicado: (2011)

Some Pharmacodynamic Aspects of Cefepime
por: Elsayed, Mossad Gamaleddin Ahmed, et al.
Publicado: (2013)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_76nras5jpcfjjtrcras51js674